Experimental studies have shown that stents implanted at the aorta become i
ncorporated within the aortic wall and can be further expanded in growing a
nimals. Few clinical studies have shown that the stent repair of severe coa
rctation of aorta provides excellent initial results, and little is known o
n the follow-up of these patients. We assessed the immediate and follow-up
results obtained in a series of 48 patients (mean age 14 +/- 12 years) with
severe coarctation of the aorta who were treated by Palmaz stent implantat
ion; 30 of them (63%) underwent angiographic follow-vp studies at a mean of
25 +/- 11 months after treatment. Quantitative serial analysis of the aort
ogram (baseline, after treatment, and at follow-up) was performed. Signific
ant relief (mean residual gradient 3 +/- 4 mm Hg) was always obtained after
scent implantation. The isthmus, when hypoplastic (60%), was always expand
ed with the stent. One associated aneurysm became occluded after the implan
t. Complications included aortic disruption, stent migration, and decreased
or absent femoral pulses. At angiographic follow-up, the stent remained al
ways in place, without recoil. in 22 patients (73%), there were no detectab
le neointimal proliferation at late angiogram; however, 8 patients (27%) ha
d some degree of intimal thickening (1 to 5 mm), causing mild restenosis in
3 patients treated at early age, and nonsignificant lumen reduction in 5.
The serial aortogram analysis revealed a minor but, significant increase in
nonstented aortic diameters that seemed related to the normal growth of ch
ildren. No need for stent reexpansion was observed at 2-year follow-up (mea
n). Two patients (7%) developed late small aneurysm formation at the stente
d wall; both were occluded by the insertion of coils through the stent orif
ices. We conclude that stent treatment for severe coarctation of aorta prov
ides excellent immediate and long-term results in young adults and children
. However, at early age, restenosis by intimal growth may develop. (C) 1999
by Excerpta Medica, Inc.